4basebio (AIM: 4BB) has appointed Jeff Coller, PhD, to its strategic advisory board (SAB).
Dr. Coller is a globally recognized expert in mRNA biology and translation. According to 4basebio, his understanding of translation efficiency and mRNA stability will help guide the company’s strategy to deliver optimised, high-fidelity DNA templates that maximise the therapeutic potential of genetic medicines.
He is the Bloomberg Distinguished Professor of RNA Biology and Therapeutics at The Johns Hopkins University and the Inaugural Director of the RNA Innovation Center. With more than 30 years dedicated to the study of mRNA, his pioneering research has fundamentally shifted the scientific understanding of gene expression, demonstrating that the genetic code acts as a master determinant of mRNA stability and transcript fate. Dr. Coller’s transformative work has not only shaped foundational RNA biology but has also accelerated the development of life-saving mRNA therapeutics and vaccines.
In a statement, Dr. Amy Walker, CEO at 4basebio, commented, “Jeff’s groundbreaking discoveries in mRNA stability and translation are nothing short of transformative for our industry. His vision aligns perfectly with 4basebio’s bold mission to dismantle the bottlenecks of traditional manufacturing. With Jeff on our strategic advisory board, we are supercharging our ability to deliver the highest-performing synthetic DNA platforms to our partners—faster, purer, and built for the future of genetic medicine.”
Dr. Coller added, “The future of mRNA therapeutics hinges entirely on the quality and scalability of the starting materials. 4basebio has engineered a truly disruptive approach to synthetic DNA manufacturing that eliminates the legacy challenges of plasmid DNA. I am thrilled to join the strategic advisory board and collaborate with a team that is redefining what is biologically and commercially possible for genetic medicines.”
